Screener
Ionis Pharmaceuticals IONS Equity Securities Fv Ni Accumulated Gross Unrealized Loss
Equity Securities Fv Ni Accumulated Gross Unrealized Loss at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedLoss.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| June 30, 2026 | Amortized / Cost | Gross Unrealized / Gains | Gross Unrealized / Losses | Estimated / Fair Value |
|---|---|---|---|---|
| Debt securities issued by states of the U.S. and political subdivisions of the states | 731 | - | (1) | 730 |
| Total debt securities with a maturity of more than one year | 651,145 | 91 | (3,911) | 647,325 |
| Total available-for-sale debt securities | $$1,788,862 | $516 | $(5,012) | 1,784,366 |
| Equity securities: | ||||
| Publicly traded equity securities included in other current assets (2) | $$11,897 | $45,670 | $(9,799) | 47,768 |
| Privately held equity securities included in deposits and other assets (3) | 10,000 | 9,816 | - | 19,816 |
| Total equity securities | 21,897 | 55,486 | (9,799) | 67,584 |
| Total available-for-sale debt and equity securities | $$1,810,759 | $56,002 | $(14,811) | 1,851,950 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss?
- Ionis Pharmaceuticals (IONS) reported equity securities fv ni accumulated gross unrealized loss of $9.8M in Q2 2026.
- How has Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss changed year-over-year?
- Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss decreased by 38.9% year-over-year, from $16.04M to $9.8M.
- What is the long-term trend for Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss has grown at a 109.1% compound annual growth rate (CAGR), from $837K to $16.01M.
- What does equity securities fv ni accumulated gross unrealized loss mean?
- This captures the cumulative gross unrealized losses on equity securities measured at fair value through net income. These losses are recognized directly in the income statement, creating potential earnings volatility. It represents the downside risk associated with the company's strategic equity portfolio.
Ask your AI about Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude